Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjögren's-like disease

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Khalili, Saeed ^a   Liu, Younan ^a   Kornete, Mara ^b   Roescher, Nienke ^c   Kodama, Shohta ^d   Peterson, Alan ^e   Piccirillo, Ciriaco A ^b   Tran, Simon D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Department of Microbiology and Immunology   (Canada)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d FUKUOKA UNIVERSITY   (Japan)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BETA1 INTEGRIN; CD11B ANTIGEN; CD45 ANTIGEN; ENDOGLIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FREUND ADJUVANT; HERMES ANTIGEN; INSULIN; STEM CELL ANTIGEN 1; TER119 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CARTILAGE CELL; CELL DIFFERENTIATION; COLONY FORMING UNIT F; CONTROLLED STUDY; FEMALE; LYMPHOCYTIC INFILTRATION; MALE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; OSTEOCYTE; REGULATORY T LYMPHOCYTE; SALIVARY GLAND; SALIVATION; SJOEGREN SYNDROME; T LYMPHOCYTE; TISSUE REGENERATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD; ANTIGENS, LY; COMBINED MODALITY THERAPY; EPIDERMAL GROWTH FACTOR; FEMALE; FIBROBLAST GROWTH FACTOR 2; FREUND'S ADJUVANT; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; MALE; MEMBRANE PROTEINS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALIVA; SALIVARY GLANDS; SJOGREN'S SYNDROME; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862015388     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038615     Document Type: Article

References (43)

1. Bayetto K, Logan RM, (2010) Sjogren's syndrome: a review of aetiology, pathogenesis, diagnosis and management. Australian dental journal 55 (Suppl 1): 39-47.
2. Delaleu N, Jonsson R, Koller MM, (2005) Sjogren's syndrome. European journal of oral sciences 113: 101-113.
3. Lee BH, Tudares MA, Nguyen CQ, (2009) Sjogren's syndrome: an old tale with a new twist. Archivum immunologiae et therapiae experimentalis 57: 57-66.
4. Lombaert IM, Brunsting JF, Wierenga PK, Faber H, Stokman MA, et al. (2008) Rescue of salivary gland function after stem cell transplantation in irradiated glands. PloS one 3: e2063.
5. Nikolov NP, Illei GG, (2009) Pathogenesis of Sjogren's syndrome. Current opinion in rheumatology 21: 465-470.
6. Tran SD, Sugito T, Dipasquale G, Cotrim AP, Bandyopadhyay BC, et al. (2006) Re-engineering primary epithelial cells from rhesus monkey parotid glands for use in developing an artificial salivary gland. Tissue engineering 12: 2939-2948.
7. Khalili S, Liu Y, Sumita Y, Maria OM, Blank D, et al. (2010) Bone marrow cells are a source of undifferentiated cells to prevent Sjogren's syndrome and to preserve salivary glands function in the non-obese diabetic mice. The international journal of biochemistry & cell biology 42: 1893-1899.
8. Tran SD, Kodama S, Lodde BM, Szalayova I, Key S, et al. (2007) Reversal of Sjogren's-like syndrome in non-obese diabetic mice. Annals of the rheumatic diseases 66: 812-814.
9. Jonsson MV, Delaleu N, Jonsson R, (2007) Animal models of Sjogren's syndrome. Clinical reviews in allergy & immunology 32: 215-224.
10. Kodama S, Davis M, Faustman DL, (2005) The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis. Cellular and molecular life sciences: CMLS 62: 1850-1862.
11. Ryu S, Kodama S, Ryu K, Schoenfeld DA, Faustman DL, (2001) Reversal of established autoimmune diabetes by restoration of endogenous beta cell function. The Journal of clinical investigation 108: 63-72.
12. Dieguez-Acuna F, Kodama S, Okubo Y, Paz AC, Gygi SP, et al. (2010) Proteomics identifies multipotent and low oncogenic risk stem cells of the spleen. The international journal of biochemistry & cell biology 42: 1651-1660.
13. Dieguez-Acuna FJ, Gygi SP, Davis M, Faustman DL, (2007) Splenectomy: a new treatment option for ALL tumors expressing Hox-11 and a means to test the stem cell hypothesis of cancer in humans. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 21: 2192-2194.
14. Faustman DL, Davis M, (2010) Stem cells in the spleen: therapeutic potential for Sjogren's syndrome, type I diabetes, and other disorders. The international journal of biochemistry & cell biology 42: 1576-1579.
15. Lonyai A, Kodama S, Burger D, Davis M, Faustman DL, (2008) The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 40: 137-146.
16. Uccelli A, Prockop DJ, (2010) Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? Curr Opin Immunol 22: 768-774.
17. Gebler A, Zabel O, Seliger B, (2012) The immunomodulatory capacity of mesenchymal stem cells. Trends Mol Med 18: 128-134.
18. Ben-Ami E, Berrih-Aknin S, Miller A, (2011) Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 10: 410-415.
19. Huntington ND, Tarlinton DM, (2004) CD45: direct and indirect government of immune regulation. Immunology letters 94: 167-174.
20. Kina T, Ikuta K, Takayama E, Wada K, Majumdar AS, et al. (2000) The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. British journal of haematology 109: 280-287.
21. Bernardo ME, Locatelli F, Fibbe WE, (2009) Mesenchymal stromal cells. Annals of the New York Academy of Sciences 1176: 101-117.
22. Roescher N, Lodde BM, Vosters JL, Tak PP, Catalan MA, et al. (2012) Temporal changes in salivary glands of non-obese diabetic mice as a model for Sjogren's syndrome. Oral Dis 18: 96-106.
23. Kodama S, Kuhtreiber W, Fujimura S, Dale EA, Faustman DL, (2003) Islet regeneration during the reversal of autoimmune diabetes in NOD mice. Science 302: 1223-1227.
24. Wu AJ, Hua H, Munson SH, McDevitt HO, (2002) Tumor necrosis factor-alpha regulation of CD4+CD25+ T cell levels in NOD mice. Proc Natl Acad Sci U S A 99: 12287-12292.
25. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317.
26. Sun S, Guo Z, Xiao X, Liu B, Liu X, et al. (2003) Isolation of mouse marrow mesenchymal progenitors by a novel and reliable method. Stem cells 21: 527-535.
27. Peister A, Mellad JA, Larson BL, Hall BM, Gibson LF, et al. (2004) Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103: 1662-1668.
28. Prockop DJ, (2009) Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths, and changing paradigms. Mol Ther 17: 939-946.
29. Garcia-Gomez I, Elvira G, Zapata AG, Lamana ML, Ramirez M, et al. (2010) Mesenchymal stem cells: biological properties and clinical applications. Expert opinion on biological therapy 10: 1453-1468.
30. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, et al. (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52: 1391-1399.
31. Delaleu N, Nguyen CQ, Peck AB, Jonsson R, (2011) Sjogren's syndrome: studying the disease in mice. Arthritis Res Ther 13: 217.
32. Hori S, Nomura T, Sakaguchi S, (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
33. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27.
34. MacDonald GI, Augello A, De Bari C, (2011) Role of mesenchymal stem cells in reestablishing immunologic tolerance in autoimmune rheumatic diseases. Arthritis Rheum 63: 2547-2557.
35. Hall BE, Zheng C, Swaim WD, Cho A, Nagineni CN, et al. (2010) Conditional overexpression of TGF-beta1 disrupts mouse salivary gland development and function. Laboratory investigation; a journal of technical methods and pathology 90: 543-555.
36. Jonsson MV, Delaleu N, Brokstad KA, Berggreen E, Skarstein K, (2006) Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland. Arthritis and rheumatism 54: 2300-2305.
37. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, et al. (2001) Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome. Clinical and experimental rheumatology 19: 131-137.
38. Roescher N, Tak PP, Illei GG, (2009) Cytokines in Sjogren's syndrome. Oral diseases 15: 519-526.
39. Klagsbrun M, (1989) The fibroblast growth factor family: structural and biological properties. Progress in growth factor research 1: 207-235.
40. Kagami H, Hiramatsu Y, Hishida S, Okazaki Y, Horie K, et al. (2000) Salivary growth factors in health and disease. Advances in dental research 14: 99-102.
41. Fujisawa K, Miyamoto Y, Nagayama M, (2003) Basic fibroblast growth factor and epidermal growth factor reverse impaired ulcer healing of the rabbit oral mucosa. Journal of oral pathology & medicine: official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 32: 358-366.
42. Nakamura H, Kawakami A, Ida H, Koji T, Eguchi K, (2007) EGF activates PI3K-Akt and NF-kappaB via distinct pathways in salivary epithelial cells in Sjogren's syndrome. Rheumatology international 28: 127-136.
43. Samuni Y, Cawley NX, Zheng C, Cotrim AP, Loh YP, et al. (2008) Sorting behavior of a transgenic erythropoietin-growth hormone fusion protein in murine salivary glands. Human gene therapy 19: 279-286.